Literature DB >> 18757774

Colon perforation during antiangiogenic therapy for malignant glioma.

Andrew D Norden1, Jan Drappatz, Abigail Slate Ciampa, Lisa Doherty, Debra Conrad LaFrankie, Santosh Kesari, Patrick Y Wen.   

Abstract

Antiangiogenic drugs have emerged as effective treatment options for patients with recurrent malignant gliomas (MGs). Though this class of drugs is generally well tolerated, rare life-threatening complications, including thromboembolism, hemorrhage, and gastrointestinal (GI) perforation, are reported. We describe six cases of GI perforation among 244 glioma patients (2.5%) during treatment with antiangiogenic agents in combination with chemotherapy and corticosteroids. Two patients succumbed to this complication, and the others recovered. Because GI perforation is a life-threatening yet treatable complication, neurooncologists must have a low threshold to consider it in patients on antiangiogenic drug therapy who present with abdominal pain and other GI complaints.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18757774      PMCID: PMC2718964          DOI: 10.1215/15228517-2008-071

Source DB:  PubMed          Journal:  Neuro Oncol        ISSN: 1522-8517            Impact factor:   12.300


  14 in total

1.  Multicenter phase II study of irinotecan, cisplatin, and bevacizumab in patients with metastatic gastric or gastroesophageal junction adenocarcinoma.

Authors:  Manish A Shah; Ramesh K Ramanathan; David H Ilson; Alissa Levnor; David D'Adamo; Eileen O'Reilly; Archie Tse; Robin Trocola; Lawrence Schwartz; Marinela Capanu; Gary K Schwartz; David P Kelsen
Journal:  J Clin Oncol       Date:  2006-11-20       Impact factor: 44.544

2.  Bowel perforation from bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.

Authors:  John H Heinzerling; Sergio Huerta
Journal:  Curr Surg       Date:  2006 Sep-Oct

3.  AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

Authors:  Tracy T Batchelor; A Gregory Sorensen; Emmanuelle di Tomaso; Wei-Ting Zhang; Dan G Duda; Kenneth S Cohen; Kevin R Kozak; Daniel P Cahill; Poe-Jou Chen; Mingwang Zhu; Marek Ancukiewicz; Maciej M Mrugala; Scott Plotkin; Jan Drappatz; David N Louis; Percy Ivy; David T Scadden; Thomas Benner; Jay S Loeffler; Patrick Y Wen; Rakesh K Jain
Journal:  Cancer Cell       Date:  2007-01       Impact factor: 31.743

4.  Outcomes and prognostic factors in recurrent glioma patients enrolled onto phase II clinical trials.

Authors:  E T Wong; K R Hess; M J Gleason; K A Jaeckle; A P Kyritsis; M D Prados; V A Levin; W K Yung
Journal:  J Clin Oncol       Date:  1999-08       Impact factor: 44.544

5.  Steroids, non-steroidal anti-inflammatory drugs, and sigmoid diverticular abscess perforation in rheumatic conditions.

Authors:  S Mpofu; C M A Mpofu; D Hutchinson; A E Maier; S R Dodd; R J Moots
Journal:  Ann Rheum Dis       Date:  2004-05       Impact factor: 19.103

Review 6.  Use of corticosteroids in neuro-oncology.

Authors:  P J Koehler
Journal:  Anticancer Drugs       Date:  1995-02       Impact factor: 2.248

Review 7.  Sigmoid diverticular perforation in neurosurgical patients receiving high-dose corticosteroids.

Authors:  H L Weiner; A R Rezai; P R Cooper
Journal:  Neurosurgery       Date:  1993-07       Impact factor: 4.654

Review 8.  Management of bevacizumab-associated bowel perforation: a case series and review of the literature.

Authors:  B D Badgwell; E R Camp; B Feig; R A Wolff; C Eng; L M Ellis; J N Cormier
Journal:  Ann Oncol       Date:  2007-11-16       Impact factor: 32.976

9.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.

Authors:  Herbert Hurwitz; Louis Fehrenbacher; William Novotny; Thomas Cartwright; John Hainsworth; William Heim; Jordan Berlin; Ari Baron; Susan Griffing; Eric Holmgren; Napoleone Ferrara; Gwen Fyfe; Beth Rogers; Robert Ross; Fairooz Kabbinavar
Journal:  N Engl J Med       Date:  2004-06-03       Impact factor: 91.245

10.  Perforation of the gastrointestinal tract in patients receiving steroids for neurologic disease.

Authors:  C E Fadul; W Lemann; H T Thaler; J B Posner
Journal:  Neurology       Date:  1988-03       Impact factor: 9.910

View more
  7 in total

1.  Anti-VEGF therapy in pituitary carcinoma.

Authors:  Leon D Ortiz; Luis V Syro; Bernd W Scheithauer; Ayca Ersen; Humberto Uribe; Camilo E Fadul; Fabio Rotondo; Eva Horvath; Kalman Kovacs
Journal:  Pituitary       Date:  2012-09       Impact factor: 4.107

2.  Phase II trial of triple tyrosine kinase receptor inhibitor nintedanib in recurrent high-grade gliomas.

Authors:  Andrew D Norden; David Schiff; Manmeet S Ahluwalia; Glenn J Lesser; Lakshmi Nayak; Eudocia Q Lee; Mikael L Rinne; Alona Muzikansky; Jorg Dietrich; Benjamin Purow; Lisa M Doherty; Debra C LaFrankie; Julee R Pulverenti; Jennifer A Rifenburg; Sandra F Ruland; Katrina H Smith; Sarah C Gaffey; Christine McCluskey; Keith L Ligon; David A Reardon; Patrick Y Wen
Journal:  J Neurooncol       Date:  2014-10-22       Impact factor: 4.130

3.  Bevacizumab salvage therapy following progression in high-grade glioma patients treated with VEGF receptor tyrosine kinase inhibitors.

Authors:  Brian J Scott; Eudocia C Quant; Margaret B McNamara; Peter A Ryg; Tracy T Batchelor; Patrick Y Wen
Journal:  Neuro Oncol       Date:  2010-02-14       Impact factor: 12.300

4.  Non-occlusive mesenteric ischemia during bevacizumab treatment for glioblastoma: a case report.

Authors:  Nozomu Oikawa; Masashi Kinoshita; Minako Yamamura; Takehiro Uno; Toshiya Ichinose; Hemragul Sabit; Tomoyuki Hayashi; Dai Inoue; Kenichi Harada; Mitsutoshi Nakada
Journal:  Acta Neurochir (Wien)       Date:  2022-07-30       Impact factor: 2.816

Review 5.  Antiangiogenic therapies for high-grade glioma.

Authors:  Andrew D Norden; Jan Drappatz; Patrick Y Wen
Journal:  Nat Rev Neurol       Date:  2009-10-13       Impact factor: 42.937

6.  Bevacizumab in high-grade gliomas: a review of its uses, toxicity assessment, and future treatment challenges.

Authors:  Gazanfar Rahmathulla; Elizabeth J Hovey; Neda Hashemi-Sadraei; Manmeet S Ahluwalia
Journal:  Onco Targets Ther       Date:  2013-04-15       Impact factor: 4.147

7.  Intestinal Perforation: A Rare Complication of Treatment With Bevacizumab.

Authors:  Ramesh Adhikari; Medha Ghose; Aysun Tekin; Simranjit Singh; Romil Singh
Journal:  Cureus       Date:  2021-03-24
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.